Trinity Biotech (TRIB) Receivables (2009 - 2025)

Trinity Biotech (TRIB) has reported Receivables for 17 consecutive years, with $43.8 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables rose 172.65% year-over-year to $43.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.8 million (up 172.65% YoY) and the FY2025 annual result came in at $43.8 million, up 172.65% from the prior year.
• Receivables improved to $43.8 million in Q4 2025 per TRIB's latest filing, from $10.9 million in the prior quarter.
• Over the last five years, Receivables for TRIB reached as high as $43.8 million in Q4 2025 and fell as low as $10.9 million in Q2 2025.
• A 5-year average of $17.3 million and a median of $16.0 million in 2022 frame the typical range for Receivables.
• The largest YoY upside for Receivables was 172.65% in 2025 against a maximum downside of 37.65% in 2025.
• Year by year, Receivables stood at $16.1 million in 2021, then dropped by 2.25% to $15.8 million in 2022, then decreased by 11.76% to $13.9 million in 2023, then gained by 15.57% to $16.1 million in 2024, then surged by 172.65% to $43.8 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $43.8 million, $10.9 million, and $16.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.